Developer docs
API playgroundTry for free, no card

Search company profiles

RoosterBio

Full company profile

uuid00004ai

Namestring
RoosterBio
Legal namestring
RoosterBio, Inc.
Websiteurl
roosterbio.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

RoosterBio is a privately held biotechnology company founded in 2012 and headquartered in Frederick, Maryland, that develops and commercializes standardized human mesenchymal stem/stromal cell (hMSC) and exosome bioprocessing solutions for the regenerative medicine and advanced therapy industry. Its product portfolio spans human primary cells from bone marrow, adipose, umbilical cord, and neonatal dermal tissue; proprietary hMSC expansion media, bioreactor feeds, and exosome production media; cGMP CliniControl clinical-grade cells, media, and genetic engineering materials supported by Type II FDA Master Files; hTERT-modified engineered cell lines; genetic engineering tools (GEM); MSC-derived exosomes with downstream processing solutions; and bundled starter, screening, and bioreactor kits. The company also offers process development, hMSC analytical, and exosome/EV analytical services.

RoosterBio sells primarily through a direct e-commerce channel supported by a sales-led B2B go-to-market targeting biotech and pharma companies, academic and research institutions, and clinical/translational research organizations across 25+ countries and 6 continents, with an exclusive distribution partnership with MineBio Life Sciences covering China. Revenue is generated mainly through one-time product sales of cells, media, kits, and cGMP materials, supplemented by professional services revenue. The company has raised approximately $41M cumulatively across disclosed rounds and SEC Form D exempt offerings, with the most recent ~$12M 2024 offering combining equity and debt securities. Scientific validation is anchored by 350+ peer-reviewed citations of RoosterBio products since 2015, and the platform is designed to lower the cost and complexity of incorporating hMSCs into therapeutic development programs from research through clinical manufacturing.

Short descriptiontext

RoosterBio is a Frederick, Maryland-based biotechnology company that develops standardized human mesenchymal stem/stromal cells, exosome bioprocessing media, and cGMP clinical-grade materials sold to biotech companies, academic researchers, and clinical-stage advanced therapy developers across 25+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersFrederick, United States
HQ citystring
Frederick
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mesenchymal stem cells, exosome bioprocessing, cell therapy media, cGMP cell products, regenerative medicine materials
Industry2 codes
PRIMARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy and Regenerative Medicine Raw Materials
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Human Primary Cells Sales
TypeOne Time License
Description

Sale of human mesenchymal stem/stromal cells from multiple tissue sources (bone marrow, adipose, umbilical cord) and engineered cell lines. Products available as research-grade and cGMP clinical-grade for therapeutic development.

roosterbio.com
2Cell & Exosome Media
TypeOne Time License
Description

Sale of specialized cell culture media, supplements, and bioreactor feed products for MSC expansion and exosome production. Includes QuickShip options for rapid fulfillment.

roosterbio.com
3Process Development & Analytical Services
TypeProfessional Services
Description

Contract services including process development support, hMSC analytical services, and exosome/EV analytical services to help customers optimize their manufacturing workflows.

roosterbio.com
4cGMP CliniControl Products
TypeOne Time License
Description

Clinical-grade raw materials and starting materials for advanced therapy manufacturing, supported by regulatory documentation including Type II FDA Master Files.

roosterbio.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1CliniControl
Description

cGMP CliniControl products for clinical-grade cell therapy manufacturing

roosterbio.com
+4 more records
Core offering1 text field

RoosterBio manufactures and sells standardized, off-the-shelf human mesenchymal stem/stromal cells (hMSCs), exosomes, and cGMP-grade cell and exosome bioprocessing media used by cell therapy developers and translational researchers. The company also offers process development and analytical services that support scale-up from research to clinical manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 350 peer-reviewed publications cite RoosterBio cells and media
+2 more records
Product overview1 text field

RoosterBio offers an integrated portfolio of products and services for mesenchymal stem/stromal cell (hMSC) and exosome-based therapeutic development. The portfolio comprises three core product lines: (1) Human Primary Cells including bone marrow-, adipose-, and umbilical cord-derived hMSCs plus neonatal dermal fibroblasts, available in standard and QuickShip™ formats; (2) Cell & Exosome Media including hMSC expansion media, bioreactor feeds, and exosome production media, available in both research-grade and cGMP CliniControl™ formats; and (3) Human Exosomes/Extracellular Vesicles including MSC-derived exosomes with QuickShip™ and downstream processing options. Supporting products include hTERT-modified engineered cell lines, genetic engineering tools, and bundled starter/screening/bioreactor kits. Services encompass process development, analytical testing for hMSCs and exosomes, and QuickShip™ solutions. The platform is designed to accelerate translation from research through clinical manufacturing, with cGMP CliniControl™ products supported by Type II FDA Master Files.

Product and service9 records
1Human Primary Cells
CategoryPrimary Cells
Description

Off-the-shelf human mesenchymal stem/stromal cells derived from bone marrow, adipose, and umbilical cord tissue, supplied to research and translational customers for use in basic and pre-clinical studies.

2Cell & Exosome Media
CategoryBioprocessing Media
Description

Defined, xeno-free bioprocessing media designed for hMSC expansion and exosome production, intended for cell therapy developers and translational researchers.

3cGMP CliniControl Products
CategoryClinical-Grade Raw Materials
Description

Clinical-grade, cGMP-manufactured hMSCs and media, supported by FDA Master Files, for use in cell therapy manufacturing intended for clinical and commercial applications.

4Engineered Cell Lines
CategoryEngineered Cells
Description

Genetically engineered human mesenchymal stem cell lines offered as research tools for disease modeling and targeted cell therapy applications.

5Genetic Engineering Tools
CategoryGenetic Engineering Reagents
Description

Reagents and tools used to genetically modify hMSCs, supporting customers developing engineered cell therapy products.

6Kits
CategoryResearch Kits
Description

Application-specific bundled kits combining primary cells, media, and protocols for targeted research workflows.

7Exosomes
CategoryExosome Products
Description

hMSC-derived exosomes supplied as standalone products for research, pre-clinical studies, and potential therapeutic development.

8Process Development Services
CategoryServices
Description

Custom bioprocess development and scale-up services helping customers translate lab-scale hMSC and exosome protocols into manufacturing-ready processes.

9Analytical Services
CategoryServices
Description

Analytical and characterization services for cells and exosomes, supporting release testing and quality control for cell therapy and exosome programs.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-08
Description

Exclusive distribution partnership where MineBio Life Sciences will supply RoosterBio's MSC and exosome bioprocessing media in China. MineBio has secured import approval for these products, enabling immediate order fulfillment. This partnership supports research-grade and cGMP manufacturing solutions for developers across China, addressing the country's growing regenerative medicine sector.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CDMO leader offering cell and gene therapy manufacturing services and cGMP-grade raw materials. Overlaps with RoosterBio's CliniControl franchise and broader cell therapy manufacturing services but operates at much greater scale across multiple modalities.

TypeBroad incumbent
Description

Diversified life science tools and bioproduction leader with Gibco cell culture media and bioprocessing consumables directly competing with RoosterBio's expansion media and bioreactor feed product lines across research and cGMP applications.

TypeBroad incumbent
Description

Danaher-owned bioprocessing platform offering bioreactors, cell culture media, and process development services. Overlaps with RoosterBio's 3D bioreactor kits, expansion media, and process development services for cell therapy manufacturing.

TypeDirect peer
Description

German-headquartered supplier of GMP-grade raw materials and cytokines for cell and gene therapy manufacturing. Closest direct competitor to RoosterBio's CliniControl cGMP products, serving overlapping clinical and commercial manufacturing customers.

TypeDirect peer
Description

Provider of cell and gene therapy manufacturing solutions including MACS GMP products, bioreactors, and process development services. Competes directly with RoosterBio's cGMP raw materials and bioprocessing platform for cell therapy developers.

TypeBroad incumbent
Description

Developer and manufacturer of purified proteins (R&D Systems) and GMP-grade cytokines used in cell therapy manufacturing. Overlaps with RoosterBio's media and ancillary raw materials offerings for clinical-stage cell therapy developers.

TypeDirect peer
Description

Supplier of cell culture media, primary cells, and tools for stem cell research and regenerative medicine. Directly comparable to RoosterBio's research-grade MSC products, expansion media, and differentiation tools across academic and industrial customers.

TypeDirect peer
Description

German supplier of primary human cells including hMSCs, along with defined cell culture media. Directly comparable niche competitor to RoosterBio's primary cells portfolio serving academic and biotech customers.

TypeEmerging player
Description

Supplier of primary cells, MSC products, and 3D tissue models for research applications. Smaller-scale emerging peer with overlapping MSC and adipose-derived cell products competing in research-grade market segments.

10Corning Life Sciences
TypeBroad incumbent
Description

Major manufacturer of cell culture vessels, surfaces, and media supplements used in MSC bioprocessing. Overlaps with RoosterBio's bioreactor and expansion media workflows through complementary consumables rather than direct product competition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RoosterBio

Cell Therapy and Regenerative Medicine Raw Materialsroosterbio.com

RoosterBio is a Frederick, Maryland-based biotechnology company that develops standardized human mesenchymal stem/stromal cells, exosome bioprocessing media, and cGMP clinical-grade materials sold to biotech companies, academic researchers, and clinical-stage advanced therapy developers across 25+ countries.

What RoosterBio does

RoosterBio is a privately held biotechnology company founded in 2012 and headquartered in Frederick, Maryland, that develops and commercializes standardized human mesenchymal stem/stromal cell (hMSC) and exosome bioprocessing solutions for the regenerative medicine and advanced therapy industry. Its product portfolio spans human primary cells from bone marrow, adipose, umbilical cord, and neonatal dermal tissue; proprietary hMSC expansion media, bioreactor feeds, and exosome production media; cGMP CliniControl clinical-grade cells, media, and genetic engineering materials supported by Type II FDA Master Files; hTERT-modified engineered cell lines; genetic engineering tools (GEM); MSC-derived exosomes with downstream processing solutions; and bundled starter, screening, and bioreactor kits. The company also offers process development, hMSC analytical, and exosome/EV analytical services.

RoosterBio sells primarily through a direct e-commerce channel supported by a sales-led B2B go-to-market targeting biotech and pharma companies, academic and research institutions, and clinical/translational research organizations across 25+ countries and 6 continents, with an exclusive distribution partnership with MineBio Life Sciences covering China. Revenue is generated mainly through one-time product sales of cells, media, kits, and cGMP materials, supplemented by professional services revenue. The company has raised approximately $41M cumulatively across disclosed rounds and SEC Form D exempt offerings, with the most recent ~$12M 2024 offering combining equity and debt securities. Scientific validation is anchored by 350+ peer-reviewed citations of RoosterBio products since 2015, and the platform is designed to lower the cost and complexity of incorporating hMSCs into therapeutic development programs from research through clinical manufacturing.

RoosterBio firmographics

Firmographics
Name
RoosterBio
Legal name
RoosterBio, Inc.
Website
https://roosterbio.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
RoosterBio is a Frederick, Maryland-based biotechnology company that develops standardized human mesenchymal stem/stromal cells, exosome bioprocessing media, and cGMP clinical-grade materials sold to biotech companies, academic researchers, and clinical-stage advanced therapy developers across 25+ countries.
Ownership category
akta.pro rank

RoosterBio industry classification

Industry
Product category
Cell Therapy and Regenerative Medicine Raw Materials
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Mesenchymal stem cells
  • Exosome bioprocessing
  • Cell therapy media
  • CGMP cell products
  • Regenerative medicine materials

Where RoosterBio is headquartered

Location

Headquarters

HQ city
Frederick
HQ country
United States
HQ region
North America

Offices1 record

Markets served

RoosterBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Human Primary Cells Sales: Sale of human mesenchymal stem/stromal cells from multiple tissue sources (bone marrow, adipose, umbilical cord) and engineered cell lines. Products available as research-grade and cGMP clinical-grade for therapeutic development.
  2. Cell & Exosome Media: Sale of specialized cell culture media, supplements, and bioreactor feed products for MSC expansion and exosome production. Includes QuickShip options for rapid fulfillment.
  3. Process Development & Analytical Services: Contract services including process development support, hMSC analytical services, and exosome/EV analytical services to help customers optimize their manufacturing workflows.
  4. cGMP CliniControl Products: Clinical-grade raw materials and starting materials for advanced therapy manufacturing, supported by regulatory documentation including Type II FDA Master Files.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels9 records

RoosterBio product offering

Product offering

Core offering

RoosterBio manufactures and sells standardized, off-the-shelf human mesenchymal stem/stromal cells (hMSCs), exosomes, and cGMP-grade cell and exosome bioprocessing media used by cell therapy developers and translational researchers. The company also offers process development and analytical services that support scale-up from research to clinical manufacturing.

Product overview

RoosterBio offers an integrated portfolio of products and services for mesenchymal stem/stromal cell (hMSC) and exosome-based therapeutic development. The portfolio comprises three core product lines: (1) Human Primary Cells including bone marrow-, adipose-, and umbilical cord-derived hMSCs plus neonatal dermal fibroblasts, available in standard and QuickShip™ formats; (2) Cell & Exosome Media including hMSC expansion media, bioreactor feeds, and exosome production media, available in both research-grade and cGMP CliniControl™ formats; and (3) Human Exosomes/Extracellular Vesicles including MSC-derived exosomes with QuickShip™ and downstream processing options. Supporting products include hTERT-modified engineered cell lines, genetic engineering tools, and bundled starter/screening/bioreactor kits. Services encompass process development, analytical testing for hMSCs and exosomes, and QuickShip™ solutions. The platform is designed to accelerate translation from research through clinical manufacturing, with cGMP CliniControl™ products supported by Type II FDA Master Files.

Differentiator

Problem solved

Functional benefit

Brands

  • CliniControl: cGMP CliniControl products for clinical-grade cell therapy manufacturing
  • QuickShip
  • RoosterVial
  • RoosterKit
  • GEM

Products and services

  • Human Primary Cells Off-the-shelf human mesenchymal stem/stromal cells derived from bone marrow, adipose, and umbilical cord tissue, supplied to research and translational customers for use in basic and pre-clinical studies.
  • Cell & Exosome Media Defined, xeno-free bioprocessing media designed for hMSC expansion and exosome production, intended for cell therapy developers and translational researchers.
  • cGMP CliniControl Products Clinical-grade, cGMP-manufactured hMSCs and media, supported by FDA Master Files, for use in cell therapy manufacturing intended for clinical and commercial applications.
  • Engineered Cell Lines Genetically engineered human mesenchymal stem cell lines offered as research tools for disease modeling and targeted cell therapy applications.
  • Genetic Engineering Tools Reagents and tools used to genetically modify hMSCs, supporting customers developing engineered cell therapy products.
  • Kits Application-specific bundled kits combining primary cells, media, and protocols for targeted research workflows.
  • Exosomes hMSC-derived exosomes supplied as standalone products for research, pre-clinical studies, and potential therapeutic development.
  • Process Development Services Custom bioprocess development and scale-up services helping customers translate lab-scale hMSC and exosome protocols into manufacturing-ready processes.
  • Analytical Services Analytical and characterization services for cells and exosomes, supporting release testing and quality control for cell therapy and exosome programs.

Quantifiable outcome

  • Over 350 peer-reviewed publications cite RoosterBio cells and media
  • +2 more outcomes

Companies that use RoosterBio

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

RoosterBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

RoosterBio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MineBio Life SciencescoreChannel Partner/ Reseller/ Distributor · 8 April 2026Exclusive distribution partnership where MineBio Life Sciences will supply RoosterBio's MSC and exosome bioprocessing media in China. MineBio has secured import approval for these products, enabling immediate order fulfillment. This partnership supports research-grade and cGMP manufacturing solutions for developers across China, addressing the country's growing regenerative medicine sector.

Scale indicators6 records

Recent moves6 records

Expansion highlights3 records

RoosterBio competitors and assessment

Company assessment

Broad incumbents

  • Lonza: Global CDMO leader offering cell and gene therapy manufacturing services and cGMP-grade raw materials. Overlaps with RoosterBio's CliniControl franchise and broader cell therapy manufacturing services but operates at much greater scale across multiple modalities.
  • Thermo Fisher Scientific: Diversified life science tools and bioproduction leader with Gibco cell culture media and bioprocessing consumables directly competing with RoosterBio's expansion media and bioreactor feed product lines across research and cGMP applications.
  • Cytiva: Danaher-owned bioprocessing platform offering bioreactors, cell culture media, and process development services. Overlaps with RoosterBio's 3D bioreactor kits, expansion media, and process development services for cell therapy manufacturing.
  • Bio-Techne: Developer and manufacturer of purified proteins (R&D Systems) and GMP-grade cytokines used in cell therapy manufacturing. Overlaps with RoosterBio's media and ancillary raw materials offerings for clinical-stage cell therapy developers.
  • Corning Life Sciences: Major manufacturer of cell culture vessels, surfaces, and media supplements used in MSC bioprocessing. Overlaps with RoosterBio's bioreactor and expansion media workflows through complementary consumables rather than direct product competition.

Direct peers

  • CellGenix: German-headquartered supplier of GMP-grade raw materials and cytokines for cell and gene therapy manufacturing. Closest direct competitor to RoosterBio's CliniControl cGMP products, serving overlapping clinical and commercial manufacturing customers.
  • Miltenyi Biotec: Provider of cell and gene therapy manufacturing solutions including MACS GMP products, bioreactors, and process development services. Competes directly with RoosterBio's cGMP raw materials and bioprocessing platform for cell therapy developers.
  • STEMCELL Technologies: Supplier of cell culture media, primary cells, and tools for stem cell research and regenerative medicine. Directly comparable to RoosterBio's research-grade MSC products, expansion media, and differentiation tools across academic and industrial customers.
  • PromoCell: German supplier of primary human cells including hMSCs, along with defined cell culture media. Directly comparable niche competitor to RoosterBio's primary cells portfolio serving academic and biotech customers.

Emerging players

  • ZenBio: Supplier of primary cells, MSC products, and 3D tissue models for research applications. Smaller-scale emerging peer with overlapping MSC and adipose-derived cell products competing in research-grade market segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

RoosterBio social profiles

Digital presence

RoosterBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RoosterBio leadership team

Management profile

Number of profiles

Profiles1 record

RoosterBio funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RoosterBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RoosterBio

What does RoosterBio do?

RoosterBio manufactures and sells standardized, off-the-shelf human mesenchymal stem/stromal cells (hMSCs), exosomes, and cGMP-grade cell and exosome bioprocessing media used by cell therapy developers and translational researchers. The company also offers process development and analytical services that support scale-up from research to clinical manufacturing.

Is RoosterBio a public or private company?

RoosterBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was RoosterBio founded?

RoosterBio was founded in 2013. It employs 51 to 100 people.

Where is RoosterBio based?

RoosterBio is headquartered in Frederick, United States, in the North America region.

How does RoosterBio make money?

Four revenue lines are on record. Human Primary Cells Sales are the primary driver. The others are cell & Exosome Media, process Development & Analytical Services and cGMP CliniControl Products.

Who are RoosterBio's main competitors?

Broad incumbents on record are Lonza, Thermo Fisher Scientific, Cytiva, Bio-Techne and Corning Life Sciences. Direct peers are CellGenix, Miltenyi Biotec, STEMCELL Technologies and PromoCell. ZenBio is listed as an emerging player.

Does RoosterBio have an API?

No public API is recorded for RoosterBio.

What industry is RoosterBio in?

RoosterBio's product category is Cell Therapy and Regenerative Medicine Raw Materials. Its primary akta.pro industry code is HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comAnalysis of Key Market Segments Driving the Pharmaceutical Filtration MarketThe pharmaceutical filtration market is projected to reach $10.01 billion by 2030, driven by the increasing development of biologics and advancements in single-use filtration technologies. Key industry players such as Xylem Inc., Sartorius AG, and RoosterBio Inc. are actively shaping this growth through strategic acquisitions and partnerships focused on purification processes.AijournRoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess SolutionsApplied StemCell and RoosterBio announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions for advanced therapy developers. The collaboration combines ASC's GMP-compatible induced pluripotent stem cell technology with RoosterBio's engineered media systems and scalable manufacturing expertise into an integrated end-to-end solution. The partnership aims to reduce complexity, accelerate timelines, and support the growing global demand for scalable, high-quality iPSC-based products across immunotherapy, neurodegenerative disease, and other therapeutic applications.PR NewswireRoosterBio and Applied StemCell Partner to Advance Scalable iPSC-Based Bioprocess SolutionsApplied StemCell and RoosterBio announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions for advanced therapies, combining ASC's GMP-compatible induced pluripotent stem cell technology with RoosterBio's engineered media systems and scalable manufacturing expertise. The collaboration aims to provide therapeutic developers with an integrated end-to-end solution that reduces complexity, improves consistency, and accelerates timelines from early research through clinical manufacturing. The partnership addresses long-standing consistency and quality gaps that have limited iPSC developers by offering a unified system complete with bioprocess media, GMP-sourced iPSCs, and manufacturing processes designed for clinical and commercial scale production.BioinformantRoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. CustomersRoosterBio, Inc. announced a distribution agreement with Qkine Ltd., a Cambridge, UK-based manufacturer of high-purity recombinant growth factors and cytokines, allowing U.S. customers to order Qkine's full product range directly from RoosterBio. The partnership positions RoosterBio as a one-stop source for cell therapy and exosome developers seeking streamlined access to critical raw materials including cells, bioprocess media, and growth factors from a single U.S.-based supplier. RoosterBio will also integrate Qkine's translation-friendly recombinant proteins into its product and process solutions for pluripotent stem cells.PR NewswireRoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. CustomersRoosterBio and Qkine announced a distribution agreement giving US customers a single source for Qkine's recombinant growth factors and cytokines. The partnership makes RoosterBio a one-stop source for cell therapy and exosome developers, with Qkine's RUO products available now. The companies aim to support translation-ready workflows for advanced therapies.PR NewswireMade Scientific and RoosterBio Announce Strategic Technology and Supply Partnership to Expand Scalable MSC and Extracellular Vesicle ManufacturingMade Scientific and RoosterBio announced a partnership integrating RoosterBio's MSC and extracellular vesicle manufacturing platforms into Made Scientific's CDMO operations. The collaboration aims to accelerate development and commercial-scale production of advanced therapies, with flask-based production supporting up to 40xCS10 scale and bioreactor transfer targeting Q2 2026.AijournRoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in ChinaRoosterBio announced an exclusive distributor partnership with MineBio Life Sciences to distribute its research-grade and CliniControl™ cGMP-grade MSC and exosome bioprocessing media throughout China. MineBio has already secured import approval for RoosterBio's products, enabling immediate order fulfillment without delay. The partnership targets China's rapidly growing regenerative medicine sector, which has one of the highest concentrations of active MSC and exosome clinical trials globally.PR NewswireRoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in ChinaRoosterBio, a Maryland-based supplier of human mesenchymal stem/stromal cells and bioprocess media, announced an exclusive distributor partnership with MineBio Life Sciences to expand access to its research-grade and CliniControl™ cGMP-grade MSC and exosome bioprocessing media throughout China. MineBio has already secured import approval for RoosterBio's products, enabling immediate order fulfillment without delay. The partnership leverages MineBio's established relationships in China's cell and gene therapy sector to support the country's rapidly growing regenerative medicine industry, which has one of the highest concentrations of active MSC and exosome clinical trials globally.Pharmaceutical TechnologyRoosterBio, MineBio team up to expand MSC solutions access in ChinaRoosterBio has entered an exclusive distributor partnership with MineBio Life Sciences to expand access to its scalable mesenchymal stem cell (MSC) and exosome bioprocessing solutions across China. MineBio will supply RoosterBio's complete product platform, including cGMP-grade media and bioreactor feeds, having already secured import clearance for the Chinese market. The partnership aims to support China's growing position as a global leader in MSC and exosome clinical research, with MineBio leveraging its established network in the regenerative medicine and cell therapy sectors.MorningstarRoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in ChinaRoosterBio has entered into an exclusive distributor partnership with MineBio Life Sciences to supply its research-grade and CliniControl cGMP-grade MSC and exosome bioprocessing media platforms throughout China. MineBio has already secured import approval for RoosterBio's products, enabling immediate order fulfillment to China's cell and gene therapy developers. The partnership leverages MineBio's established relationships in China's rapidly growing regenerative medicine sector, where Chinese institutions are conducting a significant number of MSC and exosome clinical trials.